An annual jab to protect against HIV “shows potential”, according to an early study. Millions of people around the world are ...

Researchers led by Imperial have unveiled primary trial results that show encouraging advances in HIV treatment driven by ...

Gilead plans to go straight to Phase III studies for once-yearly lenacapavir, while GSK and Viiv will push forward with their ...

UCSF researchers are the first to confirm that this approach is effective for the patients who need it most. Patients who ...

Gilead released data showing that an HIV drug, called lenacapavir, could provide virtually complete protection against ...

Researchers from Imperial College London, working with the University of Oxford and Rockefeller University, have shown ...

An American biochemist whose research has helped scientists make inroads on treating coronavirus and HIV has won this year’s ...

Two more people have been potentially cured of HIV after receiving stem cell transplants to treat blood cancer or bone marrow ...

In the fight against HIV, one of the most vulnerable populations is often overlooked - newborn babiesIt is estimated that 120,000 new HIV infections occur in children aged 14 years and younger every ...

“HIV treatment is crumbling ... s transpired over the last three or four days just takes it to a whole new level of cruelty and inhumanity and, frankly, a whole new level of stupidity ...

Dolutegravir is one of the most effective and safest HIV medicines and is used by millions of adults and adolescents living ...

Debates over tuberculosis reporting began in the late 19th century, when the bacterial infection was reframed not as a disease of the elite but of the urban poor. New York City was the first in the ...